Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00956215 · ClinicalTrials.gov registry record · NA
Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 125
- Enrollment target
NCT00956215: Completed NA study, sponsored by University of Pennsylvania.
NCT00956215 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00956215, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
Study Summary
The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively in this subset of patients.
Interventions
- DRUG Aprepitant
- DRUG Aprepitant placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00956215
The ClinicalTrials.gov registry entry for NCT00956215 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aprepitant is the first listed.
NCT00956215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00956215 about?
NCT00956215 is a clinical study titled "Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients". The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively i...
What is the current status of trial NCT00956215?
This trial is currently completed. It is a NA study. The enrollment target is 125 participants. The study started on 2010-05. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00956215?
The interventions under investigation include: Aprepitant (DRUG), Aprepitant placebo (DRUG).
Who is sponsoring clinical trial NCT00956215?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.